Clinical trials: sponsored by Bayer
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Diffuse, Large B-Cell, Lymphoma
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
To assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory Diffuse large B-cell lymphoma (DLBCL) and assess the relationship between efficacy and a…
- Trial name
- NCT02391116
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 32 sites in Australia, Belgium and 8 more
- Volunteers
- 67 people
- Sponsor
- Bayer
Carotid Stenosis
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GEMSAV (NCT01344447)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 56 sites in United States, Argentina and 12 more
- Volunteers
- 479 people
- Sponsor
- Bayer
Breast Cancer
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or…
- Trial name
- NCT01234337
- Testing
- Sorafenib (Nexavar, BAY43-9006), Capecitabine
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 537 people
- Sponsor
- Bayer
Moderate Risk of CVD
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk.
- Trial name
- ARRIVE (NCT00501059)
- Testing
- Aspirin (Acetylsalicylic acid, BAYE4465)
- Where
- 466 sites in United States, Germany and 6 more
- Volunteers
- 12,546 people
- Sponsor
- Bayer
Macular Edema
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
- Trial name
- AQUA (NCT02581995)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 76 sites in Austria, Canada and 12 more
- Volunteers
- 560 people
- Sponsor
- Bayer
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Constipation
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.
- Trial name
- NCT00770432
- Testing
- Polyethylene glycol 3350
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Bayer
Thyroid Neoplasms
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
- Trial name
- NCT00984282
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 81 sites in United States, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Bayer
Venous Thromboembolism
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. Safety will be assessed by looking at the incidence and types of bleeding events.
- Trial name
- EINSTEINJr (NCT02309411)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 29 sites in United States, Australia and 13 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
- Trial name
- STORM (NCT00692770)
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 199 sites in United States, Argentina and 26 more
- Volunteers
- 1,114 people
- Sponsor
- Bayer
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and…
- Trial name
- INHALE 1 (NCT01799993)
- Testing
- Amikacin Inhalation Solution (BAY41-6551)
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 725 people
- Sponsor
- Bayer
Thromboembolism
Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body.
- Trial name
- Einstein Jr (NCT02564718)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 9 sites in Austria, France and 5 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Coronary Artery Disease
Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Participants being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study.
- Trial name
- GadaCAD 1 (NCT01890421)
- Testing
- Gadobutrol (Gadovist, Gadavist, BAY86-4875)
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 426 people
- Sponsor
- Bayer
Prostatic Neoplasms
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3…
- Trial name
- NCT01934790
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 16 sites in United States, Finland and 5 more
- Volunteers
- 45 people
- Sponsor
- Bayer
Hypothyroidism
Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure
To investigate the incidence of detected hypothyroidism after iodinated contrast exposure in pediatric patients from birth to 3 years of age (inclusive) in a routine clinical practice setting.
- Trial name
- NCT02766283
- Testing
- iodinated contrast agents
- Where
- Israel
- Volunteers
- 843 people
- Sponsor
- Bayer
Intraabdominal Infections
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin in a pediatric population 3 months to <18 years old.
- Trial name
- MOXIPEDIA (NCT01069900)
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate
- Where
- 39 sites in United States, Argentina and 14 more
- Volunteers
- 458 people
- Sponsor
- Bayer
Neoplasms
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Phase I: Determine the maximum tolerated dose of combination of Regorafenib with Refametinib through a dose escalation study, all tumor types that meet certain inclusion/exclusion criteria can be entered.
- Trial name
- NCT02168777
- Testing
- Refametinib (BAY86-9766), Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bayer
Bronchiectasis
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14…
- Trial name
- RESPIRE 1 (NCT01764841)
- Testing
- Ciprofloxacin DPI (BAYQ3939)
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 416 people
- Sponsor
- Bayer
Pulmonary Embolism, Thromboembolism
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of…
- Conditions
- Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis
- Trial name
- EinsteinChoice (NCT02064439)
- Testing
- BAY 59-7939, ASA
- Where
- 266 sites in United States, Australia and 29 more
- Volunteers
- 3,365 people
- Sponsor
- Bayer